[1] CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures
By targeting all three, retatrutide can control hunger and metabolism more comprehensively than drugs that act on just one receptor, like GLP-1 agonists
If untreated, carnitine deficiency can lead to serious heart and liver complications
CMS has unveiled its BALANCE model, a voluntary Medicare and Medicaid coverage pathway for GLP-1s that includes price negotiations and supplemental lifestyle support, with coverage beginning in 2026 for Medicaid and 2027 for Medicare Part D [2]
d , Residue-specific intensity ratios (I/I 0 ) from c are shown
Foundayo: side effect differences Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron) are all GLP-1 receptor agonists, but they are not identical